Am J Infect Control by Anderson, Deverick J. et al.
Statewide Costs of Healthcare-Associated Infections: Estimates 
for Acute Care Hospitals in North Carolina
Deverick J. Anderson, MD, MPH1, Deborah G. Pyatt2, David J. Weber, MD, MPH2,3, William 
A. Rutala, PhD, MPH2,3, and North Carolina Department of Public Health HAI Advisory 
Group
1Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, 
Durham, NC USA
2NC Statewide Program for Infection Control and Epidemiology, UNC School of Medicine, Chapel 
Hill, NC USA
3Department of Hospital Epidemiology, University of North Carolina Health System, Chapel Hill, 
NC USA
Abstract
Background—State-specific healthcare-associated infection (HAI) cost estimates have not been 
calculated to guide Department of Public Health efforts and investments.
Methods—We completed a cost identification study by conducting a survey of 117 acute care 
hospitals in NC hospitals to collect surveillance data on patient-days, device-days, and surgical 
procedures during a one-year. We then calculated expected rates and direct hospital costs of 
surgical site infections (SSI), C. difficile infection and 3 selected device-related HAIs for hospitals 
and the entire state using reference datasets such as the National Heatlhcare Safety Network 
(NHSN).
Results—In total, 67 (53%) hospitals responded to the survey. The median bed size of 
respondent hospitals was 140 (IQR 66–350). A “standard” NC hospital diagnoses approximately 
100 HAI each year with estimated costs of $985,000 to $2.7 million. The most common HAI was 
SSI (73%). Costs related to SSI accounted for 87% to 91% of overall costs. In total, the overall 
direct annual cost of these five selected HAIs was estimated to be between $124.1 and $347.8 
million in 2009 for the State of NC.
Conclusions—Using conservative estimates, HAI led to costs of more than $100 million in 
acute care hospitals in the State of NC in 2009. The majority of costs were due to SSI.
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Introduction
Healthcare-associated infections (HAI) lead to devastating outcomes for patients and 
substantial costs to the US healthcare system. In total, HAI lead to as many as 99,000 deaths 
and costs of more than $30 billion each year in the US.1,2
This enormous burden of morbidity and mortality has caused the public, regulatory agencies 
and payers to focus on ways to reduce the consequences and costs of these infections. As a 
result, HAI and, more specifically, hospitals’ performances related to prevention of HAI are 
subject to public reporting requirements in many states.3 For example, 29 states are now 
required to report HAI data to NHSN by law.4 Similarly, Centers for Medicare and 
Medicaid Services (CMS) no longer provides payment for infection due to a central venous 
catheter and catheter-associated urinary tract infections acquired during hospitalization.5 
These “pay-for-performance” rules and other financial incentives will likely increase in 
breadth and scope as private insurers follow suit and as CMS expands the list HAI for which 
reimbursement is prohibited.
Given these growing concerns about HAI, the US Department of Health and Human 
Services developed an Action Plan to Prevent Healthcare-Associated Infections (HHS 
Action Plan) that included specific recommendations for surveillance, research, 
communication, and metrics for measuring progress towards national goals.6 Federal 
funding became available in 2009 for states to carry out the HHS Action Plan through the 
American Recovery and Reinvestment Act (P.L. 111-15).7 States receiving these funds were 
required to devise statewide plans for the creation and implementation of interventions 
designed to prevent HAI and to develop surveillance systems to monitor HAI. To date, 
however, state-specific HAI cost estimates have not been calculated to guide these efforts.
North Carolina (NC), the 10th most populous state in the US, is home to 9.6 million people 
and includes metropolitan and rural areas, several prominent industries, universities, and 
natural areas.8 The NC Department of Public Health (DPH) received ARRA funds in 2009 
to prevent HAI in acute care hospitals in NC. The DPH in turn formed an HAI Prevention 
Advisory Panel to determine the methods and identify potential targets for interventions to 
decrease the incidence of HAI in NC. A subcommittee was created to determine the cost 
impact of HAI on the State of NC in order to aid development of a long-term strategy for 
HAI prevention that included investment by the state legislature. The main goal of this 
subcommittee was to calculate the direct costs of selected HAI for acute care hospitals in 
NC and, subsequently, the state of NC.
Methods
Survey of North Carolina Hospitals
A survey was sent to 117 of the 126 acute care hospitals (median bed size 109.5, IQR 50–
204, including three long term care facilities) in NC in June, 2010. These 117 hospitals were 
selected because of their prior participation in the NC Statewide Program for Infection 
Control and Epidemiology (SPICE). Hospitals were asked to provide data for calendar year 
2009 for the following variables: licensed bed size, patient-days, ventilator-days, central 
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line-days, urinary catheter-days, number of surgical procedures, number of intensive care 
units (ICU), type of ICU, and number of infection preventionists. In addition, hospitals were 
requested to provide device-days in their ICU(s) and device days for their entire hospital 
(including the device days from the ICU(s)). Similarly, hospitals were asked to differentiate 
between surgical procedures performed in inpatient and outpatient settings. A second survey 
was sent to non-responders in July, 2010. Survey responses were averaged to determine a 
“standard” NC acute care hospital. Hospital-specific bed size data for non-responders were 
obtained from the American Hospital Association.9
Estimates for Rates of HAI
Data published by the National Healthcare Safety Network (NHSN)10 were used to 
determine mean hospital-specific rates for the following infections: central line-associated 
bloodstream infection (CLABSI), ventilator-associated pneumonia (VAP), catheter-
associated urinary tract infection (CA-UTI), and surgical site infection (SSI). NHSN 
publishes data separately for different types of locations, such as ICU type, non-ICU ward 
type, and specialty care locations (e.g., 16 distinct ICU types and 20 distinct non-ICU ward 
types for CLABSI); thus, a weighted-mean rate was calculated for each type of infection 
based on the number of device days reported to NHSN for each location. Data published by 
the Duke Infection Control Outreach Network (DICON) were used to determine the average 
rate of Clostridium difficile infections (CDI) per hospital.11
Estimates for Cost of HAIs
Minimum and maximum cost estimates were used for each of the selected HAI, based on 
published data from the CDC (Table 1).2 These estimates represent direct costs for each HAI 
in 2007 USD based on the Consumer Price Index (CPI) for Inpatient Hospital Services. 
These estimates were based on three key assumptions: 1) all NC hospitals were assumed to 
have HAI rates equal to NHSN means; 2) costs were assumed to be equal across all 
hospitals; 3) hospitals were assumed to have the same HAI rate by standardization.
Costs of HAI in North Carolina Hospitals
Numbers of each of the selected HAI were calculated for the “standard” NC hospital by 
applying the weighted-mean rates for each of the HAI from NHSN to the medians of the 
surveillance data from the survey of hospitals. For example, if the “standard” NC hospital 
accrued 2,000 central line days each year and the weighted-mean rate for CLABSI based on 
NHSN data was 2.55 CLABSIs/1,000 central line-days, then the “standard” NC hospital 
would expect to have 5.1 CLABSI each year.
These estimates were then multiplied by the minimum and maximum costs of each specific 
type of HAI to determine the annual costs for each infection for the “standard” NC hospital. 
The minimum and maximum costs for each type of infection were summed to determine 
total minimum and maximum cost estimates of HAI for the “standard” NC hospital. These 
minimum and maximum cost estimates were then multiplied by 126 (i.e., the number of 
acute care hospitals in NC) to determine minimum and maximum statewide cost estimates 
for HAIs for NC.
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Sub- and Sensitivity Analysis
A sub-analysis was performed to determine costs related to three specific categories of 
infection: device-related infections in the ICU, SSI following inpatient surgical procedures, 
and hospital-wide CDI. These categories were selected because published estimates for cost 
are most specific to these categories. This approach overcomes the limitation of 
extrapolating costs from a specific area to a broader area. For example, published data from 
CLABSIs in the ICU may not be accurate for CLABSIs that occur outside the ICU or costs 
from SSIs diagnosed following inpatient procedures may not be accurate for outpatient 
surgical procedures.
Two additional sensitivity analyses were performed. First, cost estimates were calculated 
after limiting the analysis to respondents only. That is, non-respondent hospitals were 
assumed to have zero HAI; thus, these estimates represent the most conservative estimates 
possible from our models. Second, we recalculated costs for the State by using hospital-
specific data provided by respondents, instead of calculating costs for a “standard” hospital. 
This model was created by first applying the weighted-mean rates for each of the HAIs from 
NHSN to the actual surveillance data from respondents to calculate the estimated number of 
each specific HAI for each respondent hospital. Total numbers of each of the HAI were then 
calculated by summing the results for each respondent hospital. These estimates were then 
multiplied by the minimum and maximum costs of each specific type of HAI to determine 
the annual costs for each infection for respondent hospitals. After calculating the total 
number of beds in the 126 acute care hospitals, we calculated the number of beds 
represented by respondents for each of the HAI (e.g., 62 (49%) hospitals responded with 
surgical procedure data, but these 62 hospitals represented 61% of beds in NC). The 
minimum and maximum cost estimates for each HAI were then divided by the proportion of 
beds represented to determine minimum and maximum statewide cost estimates for each 
HAI (e.g., statewide cost of SSI=total cost at respondent hospitals/0.61). Costs for each HAI 
were then summed to determine the minimum and maximum statewide cost estimates for the 
State of NC.
Statistics
Standard descriptive statistics were used to calculate means, medians, and interquartile 
ranges (IQR). Medians were compared using the Wilcoxon rank sums test. Statistical testing 
was performed using SAS v9.2 (Cary, NC).
Results
In total, 67 (53%) hospitals responded to the survey. The median bed size of respondent 
hospitals was 140 (IQR 66–350). Hospitals that responded to the survey were generally 
larger than non-responding hospitals. The median bed size for hospitals that did not respond 
was 92 (IQR 43–131; p=0.009 compared to hospitals that responded). The median number 
of Infection Preventionists (IPs) at each respondent hospital was 1 FTE (IQR 1–2). In 
general, hospitals were more likely to provide ICU-specific device data than hospital-wide 
data (Table 2).
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Respondent hospitals in NC were similar to the hospitals that reported to NHSN based on 
bed size. For example, hospitals in NC that responded to the survey and hospitals that report 
to NHSN had the same proportion of hospitals with bed size less than 200 (63% of NC 
hospitals vs. 64% of NHSN hospitals).
The “standard” NC hospital detects approximately 100 HAIs each year (Table 3). The most 
common HAI was SSI (73% of HAIs). Overall, the cost of the selected HAI in the 
“standard” NC hospital was between $985,000 and $2.7 million annually (Table 3). Costs 
related to SSI accounted for 87%–91% of overall costs. After restricting the calculation to 
costs in the ICUs for device-related infections, SSIs following inpatient surgical procedures, 
and hospital-wide CDI, the cost of HAI in the “standard” NC hospital was between 
$436,000 and $1.1 million annually.
These estimates for direct costs due to HAI for the “standard” NC hospital were then applied 
to all 126 acute care hospitals in NC. In total, the overall direct annual cost of these five 
selected HAI for the State of NC was estimated to be between $124.1 and $347.8 million. 
When our calculations were restricted to costs in the ICU for device-related infections, SSIs 
following inpatient surgical procedures, and hospital-wide CDI, the total overall direct 
annual cost of these five selected HAI for the state of North Carolina was estimated to be 
between $54.9 and $144.3 million (Table 4).
Finally, two additional sensitivity analyses were performed. First, after limiting costs to only 
respondent hospitals, the overall direct annual cost of these five selected HAI for the State of 
NC was estimated to be between $66.0 and $184.9 million. Second, we tested the 
assumption that calculating rates and costs for a “standard” NC hospital was an appropriate 
approach by creating a model that relied only on surveillance data provided by respondents. 
Using this approach, the overall direct annual cost of the five selected HAI for the State of 
NC was estimated to be between $224 and $617.7 million.
Discussion
Our study is the first to provide statewide estimates for the direct costs of HAI. Using 
estimates published by the CDC and surveillance data, we conservatively estimate that HAI 
cost the State of NC greater than $100 million each year. These estimates may help 
Departments of Public Health in other states and other advocates of infection prevention 
determine and validate potential investments in HAI prevention in their state or region. 
Finally, our methods can potentially be reproduced for other states to calculate their state-
specific HAI costs.
Of note, SSI led to the highest overall cost, accounting for approximately 90% of the costs 
of HAIs in the state of NC. Thus, our analysis suggests that initiatives to reduce the costs of 
HAI should focus primarily on preventing SSIs. Assuring knowledge of and compliance 
with national guidelines for the prevention of SSI would be a first step,12 but novel 
interventions are needed as well.
Our cost estimates for HAI have wide ranges, reflecting the difficulties in studying and 
publishing data on cost of HAI. Regardless of the actual amount or range, all studies that we 
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are familiar with have demonstrated that HAI are expensive. In addition to lost-opportunity 
costs for hospitals, HAI lead to costs to society including early deaths and disability.1,13–15 
Thus, our data provide further incentives for all hospitals and states to invest in HAI 
prevention programs. This incentive is particularly relevant because most hospitals have 
progressively received less reimbursement for patients with several types of HAI. Indeed 
this trend in declining reimbursement is likely to continue or accelerate as federal agencies 
and payers seek new ways to promote quality of care and to reduce costs. For example, 
CMS will soon initiate programs that promote “value-based purchasing programs” in which 
hospitals with higher rates of HAI will receive less support from CMS than hospitals with 
low rates. These programs will reduce margins even further for many hospitals.16
Our estimates likely underestimate the true cost of HAI in the state of NC for several 
reasons. First, respondent hospitals were generally larger than non-responding hospitals. 
Rates of some HAI and adverse outcomes such as SSI and VAP are higher in smaller 
community hospitals than medium-sized community hospitals;17–19 thus, our rate estimates 
and subsequently our cost estimates may be low, particularly since the majority of infections 
and cost were due to SSI. Second, these estimates were calculated using previously 
published estimates of direct costs of HAI and do not include indirect costs and subsequent 
costs to society from lost wage and production.20 Third, these estimates only include 5 types 
of HAIs. These HAIs constitute only 50% of HAIs;21 costs of other HAI (e.g., hospital-
acquired pneumonia in the absence of the ventilator) were not included. Fourth, the 
differential increase in costs due to HAI caused by multidrug-resistant pathogens was not 
included. Finally, our sensitivity analysis using actual surveillance data instead of 
extrapolating from a “standard” NC hospital led to higher cost estimates.
Though likely underestimations, our estimates and cost models need to be interpreted with 
caution. In fact, our goal was not necessarily to calculate a specific value for the overall cost 
of HAI but, instead, to create general estimates to help guide policy decisions and potential 
investment. HAI outcome data (as reported to the NHSN and as obtained by hospitals across 
the US) likely suffers from “surveillance bias”.22,23 Thus, surveillance data likely 
underestimate of true number of HAI occurring in hospitals in NC. In addition, cost 
considerations depend a great deal on perspective, including hospital (lost opportunity), 
patient (outcomes), and society (lost wage and production). Finally, not all HAI are 
preventable. In fact, a recent report by Umscheid et al. stated that as many as one-third of all 
cases of CLABSI and CAUTI and almost half of all cases of VAP and SSI were not 
preventable.24 Thus, our estimates do not represent the total amount of money that could 
potentially be saved through enhanced infection prevention.
Our study has other limitations. First, the biggest limitation of our study is the 53% response 
rate. Thus, our estimates may not accurately represent infection rates at non-responders. On 
the other hand, we believe that the size difference between respondent and non-responding 
hospitals would lead to an under-estimation of rates and costs, as described above. Second, 
the cost estimates published by the CDC may suffer from the same limitations of the studies 
used to create the estimates. More specifically, these studies may have had suboptimal or 
incomplete matching.25 In addition, propensity scores were not used to match cases and 
controls.26 Finally, our estimates were not adjusted for inflation.
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In summary, our study provides an estimate of the total cost of HAI for the State of NC each 
year. To our knowledge, no other groups have utilized state surveillance estimates to 
estimate state costs. The cost of HAI to hospitals in NC is staggeringly high, and SSI costs 
account for the large majority of these costs. Our efforts to estimate the costs of HAI in a 
single state should be viewed as a small but necessary step in helping other states define the 
nature of the problems facing their individual hospitals. Our estimates can also be used to 
formulate and justify the next critical steps for improving the care of hospitalized patients: 
designing, promoting and maintaining new and better programs that actually prevent HAI. 
Indeed it is necessary to define and understand the economic costs of HAI before mobilizing 
the resources and incentives to reduce the incidence of infections that generate these costs. 
Finally, costs can in turn be one of several outcomes that is used to measure the 
effectiveness of prevention efforts and to justify their costs.
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Table 1
Direct Cost Estimates for Selected HAIs in 2007 USD [3]
Type of Infection Minimum Cost Maximum Cost
Central line-associated bloodstream infection $7,288 $29,156
Ventilator-associated pneumonia $19,633 $28,508
Catheter-associated urinary tract infection $862 $1,007
Surgical site infection $11,874 $34,670
Clostridium difficile infection $6,408 $9,124
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Table 2
Summary of surveillance data from acute care hospitals in North Carolina
Variable Number of Respondents N (%) Median IQR
Patient-days 66 (99) 24980.5 (10047 – 52972)
Central line-days
 ICU 56 (84) 1031.5 (256.6 – 2837.5)
 Hospital-wide 39 (58) 1952 (366 – 6738)
Ventilator-days
 ICU 58 (87) 709 (184 – 2051)
 Hospital-wide 59 (88) 646 (168 – 2051)
Urinary catheter-days
 ICU 49 (73) 2011 (949 – 3925)
 Hospital-wide 34 (51) 2895 (1239 – 9839)
Surgical procedures (total) 62 (93) 3752 (2113 – 9637)
 Inpatient 45 (67) 1380 (400 – 3938)
 Outpatient 47 (70) 3931 (1378 – 6557)
ICU – Intensive care unit; IQR – interquartile range
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